Exploring the prognostic significance of blood carnitine and acylcarnitines in hepatitis C virus-induced hepatocellular carcinoma

Abbass, Ashraf; Sheashaey, Azza El; Fert, Ashraf El; Obada, Manar; Abdelsameea, Eman; Abdel-Samiee, Mohammed; Ibrahim, Asmaa; Khalil, Ashraf

doi:10.1186/s43066-024-00322-x

Egyptian Liver Journal

Table 3 Descriptive statistical parameters of carnitine and acylcarnitines in different groups

From: Exploring the prognostic significance of blood carnitine and acylcarnitines in hepatitis C virus-induced hepatocellular carcinoma

Group	HCC, n = 90			HCV, n = 55			Con, n = 25			KW pair wise
	M ± SD	Min–max	Med (IQR)	M ± SD	Min–max	Med (IQR)	M ± SD	Min–max	Med (IQR)	p-value < 0.05
FC0	23.39 ± 8.03	12.3–51.2	22.35 (10.2)	21.12 ± 7.17	10.33–41.2	19.7 (8.28)	13.81 ± 5.34	5.39–26.1	13.4 (7.805)	a, b
AC2	12.40 ± 4.49	3.9–25.4	11.45 (5.7725)	10.70 ± 4.30	4.42–23	9.7 (5.29)	5.87 ± 2.64	2.85–12.4	5.3 (2.78)	a, b
AC3	1.00 ± 0.51	0.25–3.1	0.895 (0.445)	0.87 ± 0.37	0.31–2.39	0.8 (0.4)	0.49 ± 0.27	0.2–1.31	0.42 (0.275)	a, b
AC3DC	0.04 ± 0.02	0.01–0.08	0.04 (0.02)	0.03 ± 0.01	0.01–0.08	0.03 (0.02)	0.04 ± 0.01	0.02–0.07	0.04 (0.01)	a, b
AC4	0.15 ± 0.12	0.05–0.8	0.11 (0.0825)	0.12 ± 0.06	0.04–0.28	0.11 (0.07)	0.07 ± 0.03	0.03–0.14	0.07 (0.03)	a, b
AC5	0.12 ± 0.07	0.06–0.6	0.105 (0.0525)	0.20 ± 0.09	0.06–0.54	0.21 (0.15)	0.15 ± 0.04	0.1–0.3	0.14 (0.025)	a, b
AC5DC	0.12 ± 0.05	0.03–0.25	0.11 (0.055)	0.10 ± 0.05	0.04–0.25	0.09 (0.05)	0.12 ± 0.04	0.01–0.2	0.12 (0.03)	a, b
AC6	0.03 ± 0.01	0.01–0.07	0.03 (0.01)	0.03 ± 0.01	0.01–0.07	0.03 (0.02)	0.03 ± 0.01	0.02–0.06	0.03 (0.01)	NS
AC8	0.04 ± 0.02	0.01–0.14	0.04 (0.02)	0.03 ± 0.02	0.01–0.13	0.03 (0.02)	0.07 ± 0.03	0.03–0.11	0.08 (0.06)	NS
AC10	0.11 ± 0.12	0.02–0.79	0.08 (0.05)	0.39 ± 0.29	0.02–0.99	0.37 (0.49)	0.15 ± 0.08	0.06–0.34	0.13 (0.16)	a, b
AC10-1	0.10 ± 0.03	0–0.2	0.09 (0.04)	0.08 ± 0.03	0.05–0.18	0.08 (0.02)	0.06 ± 0.01	0.05–0.1	0.06 (0.02)	a, b, c
AC12	0.04 ± 0.05	0.01–0.4	0.03 (0.02)	0.04 ± 0.11	0.01–0.8	0.02 (0.01)	0.02 ± 0.01	0.01–0.06	0.02 (0.01)	a, c
AC14	0.08 ± 0.10	0.02–0.9	0.06 (0.03)	0.05 ± 0.03	0.02–0.15	0.05 (0.03)	0.03 ± 0.03	0.01–0.15	0.02 (0.015)	a, b, c
AC16	1.09 ± 0.45	0.29–2.58	1.05 (0.6125)	0.84 ± 0.46	0.06–2.49	0.71 (0.56)	0.46 ± 0.24	0.1–1.02	0.46 (0.3)	a, b, c
AC18	0.66 ± 0.30	0.04–1.57	0.61 (0.365)	0.54 ± 0.27	0.17–1.51	0.5 (0.33)	0.44 ± 0.34	0.08–1.63	0.35 (0.195)	a, b, c
AC18-1	0.64 ± 0.28	0.08–1.5	0.6 (0.3725)	0.64 ± 0.35	0–1.47	0.54 (0.58)	0.40 ± 0.14	0.16–0.69	0.41 (0.145)	a, b

Con control, HCV hepatitis C virus, HCC hepatocellular carcinoma, M ± SD mean ± standard deviation, Min minimum, Max maximum, Med median, IQR interquartile range. Significance p-value < 0.05 is present when Kruskal-Wallace and pairwise tests (Mann–Whitney U) are performed across the group. Ns non-significant. ^ap < 0.05 when comparing HCC vs. Con. ^bp < 0.05 when comparing HCV vs. Con. ^ap < 0.05 when comparing HCC vs. HCV. FC0 free carnitine, AC2 acetylcarnitine, AC3 propionylcarnitine, AC4 butyrylcarnitine, AC5 isovalerylcarnitine, AC5DC glutarylcarnitine, AC6 hexanoylcarnitine, AC8 octanoylcarnitine, AC8:1 octanoylcarnitine, AC10 decanoylcarnitine, AC10:1 decenoylcarnitine, AC12 dodecanoylcarnitine, AC14 myristoylcarnitine, AC14:1 myristoleylcarnitine, AC16 palmitoylcarnitine, AC16:1 octapalmitoylcarnitine, AC18 octadecanoylcarnitine, AC18:1 oleoylcarnitine

Back to article page